Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicinal use of a kind of astragaloside compound

A technology of astragaloside IV and its application, which is applied in the field of medicinal use of astragaloside IV compounds, and can solve the problems such as difficulty in preventing and treating influenza.

Active Publication Date: 2022-01-04
THE FIFTH PEOPLES HOSPITAL OF SHANGHAI
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Flaws in vaccines and chemical drugs make it difficult to prevent and treat influenza

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal use of a kind of astragaloside compound
  • Medicinal use of a kind of astragaloside compound
  • Medicinal use of a kind of astragaloside compound

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] Embodiment 1 Astragaloside IV (AST) is to cytotoxicity assay experiment

[0031] When astragaloside IV AST was applied to MDCK cells at concentrations of 5 μg / ml, 10 μg / ml, 20 μg / ml, 40 μg / ml, 60 μg / ml, 80 μg / ml, and 100 μg / ml for 72 hours, MDCK cells were treated with 80 μg of astragaloside AST. When the concentration is 100μg / ml, there is some rounding under the light microscope, but there is no obvious toxicity, and when the concentration is 100μg / ml, there is obvious cell rounding. When the concentration is higher than 100μg / ml, the cytotoxicity is more obvious, and there is obvious cell aggregation phenomenon. The OD value of each hole was measured by MTT method, and the results showed that: when the concentration of MDCK cells was 100 μg / ml, the survival rate was more than 93%, while at 200 μg / ml, the survival rate was reduced to 30%, and when it exceeded 200 μg / ml, the cells were almost inactive ( Such as figure 1 shown). This shows that astragaloside AST has ...

Embodiment 2

[0032] Embodiment 2 Astragaloside IV (abbreviated as AST) to the inhibition experiment of influenza virus

[0033] 1. Drugs and reagents

[0034] Astragaloside IV (Astragaloside IV), measured by HPLC with a purity of ≥98%, was purchased from AMA Copoeia Reference (40mg), and was dissolved in DMSO when used; fetal bovine serum (FBS), tetramethylthiazolium blue (MTT), bovine serum Albumin (BSA) and dimethyl sulfoxide (DMSO) were purchased from Sigma, USA; trypsin-EDTA, penicillin, and streptomycin solutions were purchased from Gibco; secondary antibodies 488-labeled goat anti-mouse IgG (H+L) was purchased from Cell Signaling Technology; DAPI nuclei luminescent dye was purchased from Beyond Biotech Co., Ltd.

[0035] 2. Viruses and Cells

[0036]The throat swab samples collected from influenza-like cases were subjected to nucleic acid and virus isolation, detection and typing, and one-step RT-PCR method was used to amplify the HA gene and NA gene of a selected strain of influe...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an application of an astragaloside IV compound or a pharmaceutical composition containing it in the preparation of anti-influenza B virus medicine. Astragaloside IV AST not only has obvious inhibitory effect on the proliferation of influenza B virus in MDCK cells, but also has no cytotoxic effect within the safe concentration range, and has high safety. It is expected to become a clinical anti-influenza B drug with broad application prospects .

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to the medicinal use of astragaloside IV compounds. Background technique [0002] Influenza is an acute respiratory disease caused by influenza virus, which has the characteristics of wide range of hosts, rapid spread and high morbidity rate. Influenza virus is easy to cause influenza pandemic, and its mortality rate is higher than that of seasonal influenza, which poses a serious threat to human and animal life and health. Influenza A and B are two different types of viruses that cause influenza. In addition to infecting humans, influenza A virus also widely exists in animals such as poultry, pigs, horses, seals, whales, and minks. Influenza B viruses mainly circulate in the human body and cause seasonal influenza, which tends to be prevalent in winter and spring. Influenza A virus is a new subtype produced by antigen mutation, which often causes a worldwide pandemic. The vari...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/7048A61P31/16A61P11/00
CPCA61K31/7048A61P31/16A61P11/00
Inventor 梅周芳揭志军陈鸿军
Owner THE FIFTH PEOPLES HOSPITAL OF SHANGHAI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com